An unpublished research article inside the Centers for Disease Control and Prevention has become the focus of a new transparency dispute, after tipsters claimed the acting director intervened to stop its release because it strongly supported COVID vaccine performance.
According to people familiar with internal discussions, the draft paper reportedly analyzed post‑authorization surveillance data, including pharmacovigilance signals and vaccine effectiveness estimates derived from real‑world cohorts. The study was said to show reduced hospitalization and mortality among vaccinated groups, using standard epidemiological tools such as relative risk and confidence intervals. Critics inside the agency now argue that burying a pro‑vaccine analysis undermines the very risk‑benefit assessment regulators ask the public to trust.
The alleged block has renewed long‑running concerns about scientific integrity policies that are meant to firewall biostatistics and peer review from political or reputational pressure. Public health law experts say any perception of selective publication, whether the findings are favorable or unfavorable to vaccines, erodes institutional credibility and distorts the information entropy that shapes public debate. External watchdogs are already calling for disclosure of the study protocol, anonymized datasets, and the full review history, turning an obscure internal manuscript into a test of how the agency handles contested evidence.
